Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Current Income Tax Expense in Foreign Jurisdictions by Year
Current Income Tax Expense in Foreign Jurisdictions ($M)
Novartis Current Income Tax Expense in Foreign Jurisdictions: $1,348M in FY2025, down 9.3% from a year earlier.
Latest, FY2025
1,348
Period ended Dec 31, 2025
Change on a year earlier
-9.3%
1,486 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Note 6.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Current Income Tax Expense in Foreign Jurisdictions ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,348 | -9.3% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 1,486 | +15.2% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 1,290 | +11.7% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2022 | Dec 31, 2022 | 1,155 | +18.7% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2021 | Dec 31, 2021 | 973 | -16.7% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2020 | Dec 31, 2020 | 1,168 | +21.5% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2019 | Dec 31, 2019 | 961 | -2.7% | Novartis Form 20-F (0001370368-22-000010) ↗ |
| FY2018 | Dec 31, 2018 | 988 | -31.9% | Novartis Form 20-F (0001370368-21-000006) ↗ |
| FY2017 | Dec 31, 2017 | 1,451 | +2.3% | Novartis Form 20-F (0001370368-20-000003) ↗ |
| FY2016 | Dec 31, 2016 | 1,418 | – | Novartis Form 20-F (0001370368-19-000002) ↗ |
Cite this data
StockData. (2026). Novartis Current Income Tax Expense in Foreign Jurisdictions ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/tax-curr-foreign
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.